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ABCD1X-linked adrenoleukodystrophy (X-ALD) is the most frequent peroxisomal disease. The two main clinical
phenotypes of X-ALD are adrenomyeloneuropathy (AMN) and inﬂammatory cerebral ALD that manifests ei-
ther in children or more rarely in adults. About 65% of heterozygote females develop symptoms by the age of
60 years. Mutations in the ABCD1 gene affect the function of the encoded protein ALDP, an ATP-binding-
cassette (ABC) transporter located in the peroxisomal membrane protein. ALDP deﬁciency impairs the perox-
isomal beta-oxidation of very long-chain fatty acids (VLCFA) and facilitates their further chain elongation by
ELOVL1 resulting in accumulation of VLCFA in plasma and tissues. While all patients have mutations in the
ABCD1 gene, there is no general genotype–phenotype correlation. Environmental factors and a multitude
of modifying genes appear to determine the clinical manifestation in this monogenetic but multifactorial dis-
ease. This review focuses on the clinical, biochemical, genetic and pathophysiological aspects of X-ALD. This
article is part of a Special Issue entitled: Metabolic Functions and Biogenesis of Peroxisomes in Health and
Disease.
© 2012 Elsevier B.V. All rights reserved.1. Clinical aspects of X-ALD
X-linked adrenoleukodystrophy (X-ALD) is clinically character-
ized by two main phenotypes: adrenomyeloneuropathy (AMN) and
the cerebral demyelinating form of X-ALD (cerebral ALD) [1,2]. AMN
and cerebral ALD occur frequently within the same family and there
is no correlation between X-ALD phenotype and mutations in the
ABCD1 gene (see below). Cerebral ALD presents usually with a rapidly
progressive inﬂammatory demyelination within the brain resulting in
severe cognitive and neurologic disability, a vegetative state within
two to ﬁve years of clinical symptom onset and death thereafter.
This phenotype is most common during childhood (childhood cere-
bral ALD; CCALD) and adolescence (adolescent cerebral ALD), but
up to 20% of adult males initially presenting with AMN will develop
cerebral ALD later in life [3]. The pathology of AMN is fundamentally
different from that of cerebral ALD and is characterized predominant-
ly by a noninﬂammatory distal axonopathy involving mostly the long
tracts of the spinal cord that results in a progressive spastic paraplegia
[1,2].lic Functions and Biogenesis of
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rights reserved.1.1. Adrenomyeloneuropathy (AMN) in males and heterozygous women
AMN is the most frequent phenotype of X-ALD [1,2]. A newborn
malewithX-ALD, as identiﬁed by amutation in the ABCD1 gene, is likely
to develop AMN in adulthood. The ﬁrst symptoms of AMN usually ap-
pear when male patients are between 20 and 30 years but usually be-
fore the ﬁfth decade [3]. Initially, the neurologic disability is slowly
progressive. The diagnosis of AMN is rarely made during the ﬁrst
3–5 years of clinical symptoms, unless other cases of X-ALD have been
identiﬁed in the same family. AMNmales develop progressive stiffness
and weakness of the legs, impaired vibration sense in the lower limbs,
sphincter disturbances and impotence. Although nerve conduction
studies suggest very frequently the presence of axonal and/or demye-
linating neuropathy in AMN males, the clinical burden of peripheral
nerve involvement is often difﬁcult to assess because of prominent spi-
nal cord symptoms [4]. Adult males with AMN frequently have scanty
scalp hair that often develops during adolescence.
In an earlier study, half of heterozygous women were shown to
have AMN symptoms [5]. An increased number of heterozygous
women with AMN symptoms are now being identiﬁed as the ﬁrst
member of their family to be affected by X-ALD and the real incidence
of AMN in heterozygous women is likely to be close to 65% by the age
of 60 years (Engelen et al., manuscript in preparation). In general, the
onset of neurologic symptoms occurs at a later age than in males with
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and disease progression are generally less severe but some heterozy-
gous women are as severely impaired as male patients with X-ALD.
Peripheral nerve involvement is observed less frequently. Scanty
scalp hair can also be found in heterozygotes.
The evolution of AMN in adult males and heterozygous women is
quite variable; a relapsing and remitting evolution is never seen. In
two-thirds of AMN patients, the neurologic disability progresses
slowly. Within 10–15 years, motor disability becomes severe and re-
quires the use of a cane or a wheelchair. However, 35% of patients
with AMN have a marked progression of their myelopathy within
the ﬁrst 3–5 years of clinical symptom onset. Adrenocortical insufﬁ-
ciency (Addison's disease) is present in approximately two-thirds of
males with AMN but is often latent without evident clinical manifes-
tations, including melanoderma. Addison's disease is present in less
than 1% of heterozygous women. Of note, however, the clinical diag-
nosis of Addison's disease can be made in males with X-ALD, years or
even decades before the onset of neurological AMN symptoms.
A moderate increase of the brain MRI signal of the white matter in
the centrum ovale on FLAIR sequences is frequently seen several
years after onset of symptoms. Furthermore, there can be abnormal
hypersignal of the pyramidal tracts in brainstem and internal cap-
sules on FLAIR and T2 sequences. There is no cerebral demyelination
based on abnormal hypersignal on FLAIR and T2 sequences in the
parieto-occipital or frontal white matter MRI of the brain [3,6]. Cere-
bellar atrophy with or without demyelination of the cerebellar white
matter may also appear. As the disease progresses, MR spectroscopy
shows in the cerebral white matter a decrease of N-acetyl-aspartate
(NAA)/creatinine ratio reﬂecting axonal loss and an increase of
choline/creatinine and myo-inositol/creatine ratios reﬂecting lipid
turn-over changes [7]. MRI of the spinal cord shows non-speciﬁc atro-
phy but without gadolinium enhancement as it can be observed in
multiple sclerosis. More sophisticated MR techniques such as magne-
tization transfer or diffusion tensor-based imaging may however
show abnormalities in the lateral and dorsal columns of the spinal
cord and in the cortico-spinal tracts from spinal cord to brain [8–10].
Evoked potentials show delayed responses, ﬁrst of brainstem
evoked responses, then of motor evoked responses of lower limbs,
and last of somatosensory-evoked responses of the lower limbs
[11]. Visual evoked responses are usually normal or show moderate
increase of P100 latency. Electromyography and nerve conduction ve-
locities demonstrate the presence of axonal and/or demyelinating
polyneuropathy in the lower limbs of 75% of AMN males and 40% of
women with AMN [4]. The differential diagnosis of AMN includes
other hereditary forms of spastic paraplegia and the primary progres-
sive form of multiple sclerosis.
Twenty percent of AMN males develop, usually between 20 and
35 years of age, a cerebral demyelinating form of the disease [3].
This risk decreases markedly after the age of 45 years. The progres-
sion of demyelinating lesions is initially slower than in boys with ce-
rebral ALD. After several months or years of progression, cerebral ALD
may even arrest, but once the cerebral demyelinating lesions become
inﬂammatory with evidence of enhanced contrast of the demyelinat-
ing lesions after intravenous injection of gadolinium, cerebral ALD in
adult males has the same poor prognosis as in boys with inﬂammato-
ry cerebral ALD. The occurrence of cerebral ALD in females is
exceptional.
1.2. The cerebral demyelinating form of X-ALD
Cerebral ALD is the most severe phenotype of X-ALD. A newborn
male with an ABCD1 gene mutation has a 35–40% risk to develop ce-
rebral ALD between the ages of 5 and 12 years. As mentioned above,
20% of adult AMNmales are also at risk to develop cerebral ALD. Over-
all, for male X-ALD patients the lifetime risk to develop cerebral ALD,
either in childhood or in adulthood, is around 60%. There is an age-related correlation with the onset of cerebral ALD and disease pro-
gression: the earlier the onset of cerebral demyelination, the more
rapid the progression of the disease. Patients are neurologically unaf-
fected until they develop cerebral demyelination visible on brain MRI
(as abnormal hypersignal of white matter on T2 and FLAIR sequences,
hyposignal of white matter on T1 sequences) [1,12,13]. Usually the
initial lesions involve either the splenium of the corpus callosum
and then extend into the adjacent white matter of the parieto-
occipital lobes (Fig. 1A) or alternatively the genu of the corpus callo-
sum and then extend into the white matter of the frontal lobes. Initial
demyelinating lesions may also occur in the pyramidal tracts, within
the brainstem or internal capsule (Fig. 1B) and then extend into the
centrum semiovale (frontal white matter). The cerebral demyelinat-
ing lesions can be asymmetric, particularly when previous head trau-
ma or even stroke seems to have initiated the onset of cerebral ALD.
Initially, the demyelinating lesions are not inﬂammatory (based on
absence of lesion enhancement on T1 sequences after peripheral in-
jection of gadolinium) and progress slowly. The patients have virtual-
ly no neurologic symptoms, except sometimes mild cognitive
dysfunctions. Suddenly, the disease becomes inﬂammatory (with ev-
idence of demyelinating lesion enhancement after peripheral injec-
tion of gadolinium) and at this stage the disease starts to progress
rapidly. The patients enter then into an active phase of devastating
neurologic and cognitive deterioration that includes emotional labili-
ty, hyperactive behavior, school failure for boys, and either visuo-
spatial impairment or frontal syndrome according to the sites of
cerebral demyelinating lesions. This cognitive deterioration is rapidly
associated with neurologic deﬁcits such as hemiplegia or quadripar-
esis, cerebellar ataxia, impaired central auditory discrimination, visu-
al ﬁeld defects, cortical blindness and often seizures. Eventually, a
vegetative state ensues within two to ﬁve years leading to death at
varying intervals thereafter. Approximately 65% of children or adults
with cerebral ALD have adrenocortical insufﬁciency that can precede
the onset of neurologic symptoms for years or decades.
About 10% of boys with cerebral ALD may not enter into the active
inﬂammatory and devastating stage of the disease. The same may
occur in adult males with cerebral ALD. This phenotype is often re-
ferred to as “chronic or arrested cerebral X-ALD”. With white matter
lesions involving either the parieto-occipital or the frontal white mat-
ter, these patients end up developing marked visual–spatial or execu-
tive cognitive deﬁcits, but without signiﬁcant neurological or sensory
(visual, auditive) symptoms. After an initial progression of the demy-
elinating lesions that often result in loss of myelin and ventricular di-
latation and cortical atrophy, the patient can remain stable for a
decade or even longer. But a full progression to the inﬂammatory
stage remains possible, even after 10 to 15 years without progression
of cerebral demyelination. Electrophysiological tests are useless for
the early diagnosis of cerebral ALD as brainstem visual evoked re-
sponses become abnormal only in the advanced stage of the disease.
The occurrence of childhood cerebral ALD in females is exceptional.
It is hypothesized and partially supported by laboratory studies that
the few girls who developed CCALD had skewed X-inactivation to-
ward the X-chromosome carrying the mutated ABCD1 gene (Kemp,
unpublished data).
1.3. Other X-ALD phenotypes
Rarely, X-ALDmales remain completely asymptomatic, even with-
out signs of adrenocortical insufﬁciency, up to the age of 40–50 years.
About one-third of heterozygous women remain free of clinical
symptoms during their entire life. Adrenocortical insufﬁciency may
be the ﬁrst manifestation of X-ALD in boys or adults. About 10% of
X-ALD males have only primary adrenocortical insufﬁciency (Addi-
son's disease) initially without evidence of nervous system involve-
ment at one time of their life (either in childhood or adulthood)
[14]. These patients are, however, at risk to develop AMN or cerebral
Fig. 1. (A) Brain MRI (axial images; FLAIR sequence) showing abnormally increased
signal in the splenium of the corpus callosum, the parieto-occipital white matter, the
visual pathways (optic radiations and lateral geniculate bodies), as well as the medial
geniculate bodies of auditory pathway and the posterior limbs of the internal capsules.
The demyelinating lesions are extensive and correspond to an advanced disease stage.
(B) Brain MRI (axial images; FLAIR sequence) showing abnormally increased signal in-
volving the posterior and anterior limbs of the left and right internal capsule.
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phenotype is fully penetrant in adults after the age of 55 years.
Asymptomatic males with X-ALD after this age are extremely rare.
Adult X-ALD males may develop testicular insufﬁciency due to in-
volvement of Sertoli and Leydig cells that sometimes results in clini-
cal symptoms leading to a diagnosis of X-ALD. However, most of
these patients already had clinical signs of AMN at the time they de-
veloped testicular insufﬁciency. Heterozygous women have no endo-
crine problems, except for the presence of adrenocortical insufﬁciency
in b1% of cases.
2. Biochemical aspects
2.1. The biochemical defect in X-ALD
By the early 1970s, twelve fully documented clinical reports were
available describing boys with adrenocortical atrophy and diffuse cere-
bral sclerosis in combinationwith strong evidence of an X-linked reces-
sive mode of inheritance. Biochemical analysis of the brain at autopsy
revealed the ﬁrst clue pointing toward an underlying metabolic cause.Using thin layer chromatography Forsyth and coworkers demonstrated
an increase in esteriﬁed cholesterol in the white matter and cortex of
the occipital and parietal lobes. Based on this ﬁnding the authors pro-
posed X-ALD as an inborn error of metabolism common to the adrenal
cortex and the brain [15]. In 1973, Powers and Schaumburg demon-
strated unusual striations in the inner adrenocortical cells which were
shown to consist of intracytoplasmic lamellae and lamellar lipid inclu-
sions by electron microscopy [16]. Lipid inclusions were also found in
testicular cells, Schwann cells and brain macrophages from patients
withX-ALD [16]. Johnson and coworkers demonstrated that the striated
material from adrenal and cerebral white matter was resistant to ace-
tone and ethanol extraction, but readily soluble in nonpolar solvents
such as hexane and chloroform [17]. This suggested the accumulation
of an unusually nonpolar material in these tissues. Subsequently, bio-
chemical analysis of the inclusion bodies revealed that they contained
cholesterol, phospholipids and gangliosides esteriﬁed with saturated
very long-chain fatty acids (VLCFA) [18]. These ﬁndings deﬁned X-
ALD as a lipid-storage disease and led to the hypothesis that aberrant
metabolism of the VLCFA is the key factor in the pathogenesis of X-
ALD. This hypothesis was conﬁrmed by Singh and coworkers with the
demonstration that the oxidation of C24:0 and C26:0 is reduced in ﬁ-
broblasts from X-ALD patients, whereas oxidation of radiolabeled
C16:0 was fully normal in X-ALD cells [19]. Osmundsen demonstrated
that hepatocytes of cloﬁbrate-treated rats showed a marked increase
in the C22:1 beta-oxidation capacity. This observation prompted the
conclusion that VLCFA are oxidized in non-mitochondrial subcellular
compartments [20]. Next, Singh and coworkers showed that in rat
liver and cultured human skin ﬁbroblasts radiolabeled C24:0 is oxidized
mainly and possibly exclusively in peroxisomes and that it is this sys-
tem that is defective in X-ALD [21]. More recently it has been demon-
strated that stable isotope-labeled fatty acids, like D3-C22:0 [22] and
D3-C24:0 [23] can be used as an alternative to 1-[14C]-labeled C24:0
for studying fatty acid metabolism. The peroxisomal beta-oxidation ac-
tivity is calculated from the amounts of D3-C16:0 generated intracellu-
larly. In ﬁbroblasts derived from patients with a defect in one of the
peroxisomal beta-oxidation enzymes, such as acyl-CoA oxidase (AOX)
deﬁciency and bifunctional protein (DBP) deﬁciency, no D3-C16:0
could be detected [23]. These data conﬁrmed that beta-oxidation of
VLCFA takes place exclusively in peroxisomes and not in mitochondria.
The discovery by Moser and coworkers that VLCFA (in particular
C26:0) are also elevated in readily accessible materials like blood
cells and plasma of X-ALD patients has been of crucial importance
for the diagnosis of X-ALD [24]. This ﬁnding allowed unequivocal
identiﬁcation of male patients. Today, plasma VLCFA analysis is still
the best initial biomarker for the diagnosis of X-ALD. Three parame-
ters are analyzed: the amount of C26:0 and the ratios of C24:0/
C22:0 and C26:0/C22:0 [24]. Plasma VLCFA analysis is recommended
in all male patients with progressive spastic paraparesis of unknown
cause, Addison's disease and those presenting typical pattern of cere-
bral demyelination at brain MRI. In males, unambiguous diagnosis of
X-ALD can be achieved by demonstration of elevated levels of VLCFA
in plasma. In women who are heterozygous for X-ALD plasma VLCFA
levels often are increased. However, it should be stressed that studies
in obligate heterozygotes have shown false negative results in ap-
proximately 20% of cases [14]. Thus, a normal plasma VLCFA level
does not exclude heterozygosity for X-ALD. Therefore, mutation anal-
ysis is the most reliable method for the identiﬁcation of heterozy-
gotes, provided that the mutation in the family has been deﬁned in
an affected male or obligate heterozygote relative [25]. However, it
is our experience that more and more symptomatic heterozygous
women with AMN are identiﬁed as the index patient in a family.
ElevatedVLCFA levels are present inmany different lipid species in X-
ALD patients. The greatest excess has been reported in the ganglioside,
phosphatidylcholine, sphingomyelin, cerebroside and sulfatide ester
fractions [18,26–29]. VLCFA are not elevated in the phosphatidylinositol
ester fraction and the level of nervonic acid C24:1 (n-9) is reduced in the
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have also been reported. For example, the hydrophobic myelin proteoli-
pid protein (PLP) contains covalently bound long-chain fatty acids
(mainly C16:0, C16:1, C18:0 and C18:1)which are attached to intracellu-
lar cysteine residues via thioester linkages [30]. In X-ALD there is an in-
crease in the amount of VLCFA bound to PLP [27]. Recently, combined
liquid chromatography-tandem mass spectrometry showed that VLCFA
are highly enriched in the lysophosphatidylcholine (lysoPC) fraction
[31], providing the basis for newborn screening for X-ALD [32].
Reinecke and coworkers combined histopathological and bio-
chemical analyses of the brain and demonstrated that VLCFA accumu-
late in morphological normal brain indicating that the biochemical
abnormality precedes histopathological changes [33]. These data
were conﬁrmed by Theda and coworkers who found that in regions
in which myelin was intact the phosphatidylcholine fraction showed
the highest VLCFA excess (16-fold higher) which led these authors to
conclude that the phosphatidylcholine abnormalities in X-ALD may
well be a critical factor in the pathogenesis of the disease [28]. In
2005, Asheuer and coworkers demonstrated that brain VLCFA levels
in normal appearing white matter correlate with the clinical pheno-
type [34]. In comparison with age-matched controls, C26:0 levels
were increased 3-fold in CCALD patients, and 1.9-fold in AMN pa-
tients. Taken together, these results show that the accumulation in
brain VLCFA levels precedes histopathological alterations and are an
important factor in the development of cerebral disease.
2.2. Toxicity of VLCFA
VLCFA are extremely hydrophobic and they have different physio-
logical properties than long-chain fatty acids. The rate of desorption
from biological membranes decreases exponentially with increasing
chain length. The desorption of C26:0 from a phospholipid bilayer
model membrane is 10,000 times slower than that of C16:0 and
C18:0 fatty acids [35]. Microcalorimetric studies have shown that in-
clusion of C26:0 in a model membrane disrupts membrane struc-
ture [35]. This is in agreement with an earlier report that
demonstrated an increased membrane microviscosity in erythrocytes
isolated from patients with X-ALD [36]. Whitcomb and coworkers
provided a more physiological demonstration that VLCFA affect mem-
brane function by assessing the effect of VLCFA on ACTH-stimulated
cortisol release in cultured human adrenocortical cells [37]. The addi-
tion VLCFA to the culture medium in concentrations equivalent to
those in X-ALD plasma led to an increased microviscosity of adreno-
cortical cell membranes and a decreased ACTH-stimulated cortisol se-
cretion. The authors concluded that the VLCFA excess altered the
membrane structure and suppressed the availability of the ACTH
receptor.
Hein and coworkers provided some insight into the cytotoxic effect
of VLCFA on neural cells by studying the physiological consequences of
VLCFA addition to cultures of oligodendrocytes, astrocytes and neurons
thatwere isolated from rat brain [38]. Exposure of oligodendrocytes and
astrocytes to 20 μM C22:0, C24:0 and C26:0 caused cell death within
24 h. In contrast, cell death was not seen when the cells were chal-
lenged with up to 100 μM C16:0. Challenging neural cells with VLCFA
induced depolarization of mitochondria in situ and induced deregula-
tion of intracellular calcium homeostasis. Interestingly, VLCFA were
most toxic to the myelin-producing oligodendrocytes [38]. The authors
did not ﬁnd any evidence for the formation of reactive oxygen species
(ROS). Based on the results obtained the authors concluded that
VLCFA cause cell death by a combination of a disturbance in calcium
homeostasis and mitochondrial dysfunction, but not primarily via
ROS-production. It should be noted, however, that based on these
results the involvement of ROS in X-ALD pathogenesis can not be ex-
cluded because: 1) the cells were exposed to VLCFA for a short time
period, and 2) the cells usedwere derived fromwild type rats. Fourcade
and coworkers presented evidence of oxidative damage to proteins inthe spinal cord of ABCD1 knockout mice at the age of 3.5 months [39].
This is long before the ﬁrst neuropathological lesions in the spinal
cord become apparent at around 16 months of age and the onset of clin-
ical signs at 20 months of age [39,40]. Eichler and coworkers addressed
the in vivo cytotoxic effect of VLCFA complexed to phospholipids by
injecting lysophosphatidylcholine containing C24:0 (C24:0-lysoPC) to
the cortex of wild type mice [41]. This resulted in microglial activation
and apoptosis. Interestingly, C16:0-lysoPC injections did not cause
these effects. This indicates a fatty acyl chain length dependent cytotox-
icity and suggests that microglial apoptosis caused by toxic levels of
VLCFA containing lysoPC may constitute an early pathogenic change
in cerebral X-ALD.
2.3. VLCFA metabolism
Free fatty acids are in general metabolically inactive. They must be
activated by thioesteriﬁcation to their coenzyme-A form in order to be-
come metabolically active. Based on the initial demonstration by
Hashmi and coworkers that the activation of VLCFA to their respective
CoA-esters is deﬁcient in X-ALD ﬁbroblasts [42], it was anticipated
that ALDP would have VLCFacyl-CoA synthetase activity. It therefore
came as a surprise that when the ABCD1 genewas identiﬁed, its product
(ALDP) was not a VLCFacyl-CoA synthetase, but a peroxisomal mem-
brane protein belonging to the ATP-binding cassette (ABC) superfamily
of transporters [43]. It has now been demonstrated that the fatty acid
transport protein 4 (FATP4) encoded by the SLC27A4 gene is the fatty
acyl-CoA synthetase that preferentially activates VLCFA to their CoA de-
rivatives [44]. Compared to control cells, ﬁbroblasts derived from
FATP4-deﬁcient mice had an 83% decrease in C24:0 activation. The per-
oxisomal C24:0 beta-oxidation capacity was reduced by 58% in
FATP4−/− cells, and the rates of incorporation of C24:0 into several
lipids, including triacylglycerol, cholesterol esters, and major phospho-
lipid species, was reduced by more than 50% [44]. FATP4 is present at
multiple subcellular locations which include peroxisomes, mitochon-
dria and endoplasmic reticulum. Thus, FATP4 appears to provide acti-
vated VLCFA for most major lipid catabolic and anabolic pathways.
The peroxisomal beta-oxidation machinery required for the oxida-
tion of C26:0-CoA is completely normal inX-ALDpatients. Based on com-
plementation studies demonstrating that expression of normal ABCD1
cDNA in X-ALD patient ﬁbroblasts restored VLCFA beta-oxidation [45]
and reduced VLCFA to normal levels [46], it has long been hypothesized
that ALDP transports VLCFA across the peroxisomal membrane. Yeast
has proved to be a valuable model system in the search for the function
of ALDP. Disruption of either Pxa1p or Pxa2p, which are the yeast ortho-
logs of the human ABCD proteins, results in the deﬁcient peroxisomal
beta-oxidation [47]. The Pxa1p/Pxa2p heterodimer is involved in the
transport of a spectrum of acyl-CoA esters across the peroxisomal mem-
brane [48,49]. Expression of ALDP in the pxa1/pxa2Δ doublemutant par-
tially rescued the mutant phenotype which implies the involvement of
ALDP in the transport of acyl-CoA esters across the peroxisomal mem-
brane [49]. Subsequent studies using human X-ALD ﬁbroblasts by
Ofman and coworkers showed that a deﬁciency in ALDP indeed results
in a strong elevation in the levels of C24:0-CoA and C26:0-CoA esters
conﬁrming a VLCFacyl-CoA transport deﬁciency in X-ALD [50]. These
data establish that ALDP transports VLCFacyl-CoA into peroxisomes
and that ALDP deﬁciency in X-ALD has two major effects: 1) it impairs
peroxisomal VLCFA beta-oxidation and 2) it raises cytosolic VLCFacyl-
CoA levels [50]. The elevated levels of VLCFacyl-CoA esters in the cytosol
are substrate for further elongation to even longer fatty acids by ELOVL1,
the human C26-speciﬁc elongase [50,51].
2.4. Origin of VLCFA
The VLCFA that accumulate in X-ALD are only partly absorbed
from the diet [52]. Tsuji et al. demonstrated that the majority results
from endogenous synthesis through elongation of long-chain fatty
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ences in C26:0 levels of X-ALD ﬁbroblasts cultured in lipid-free media
or under standard tissue culture conditions [54]. In addition, dietary
restriction of VLCFA did not lower plasma C26:0 levels in patients
with X-ALD [55]. As a result of the impaired VLCFA degradation due
to the deﬁcient import of VLCFA-CoA into peroxisomes, the synthesis
of VLCFA is enhanced in X-ALD [56].
Fatty acids up to 16 carbon atoms in length are synthesized in the cy-
tosol by themultifunctional protein fatty acid synthase (FAS)which uti-
lizes acetyl-CoA, malonyl-CoA and NADPH to elongate fatty acids in
two-carbon increments [57]. The synthesis of saturated VLCFA, mono-
unsaturated VLCFA (MUFA) and polyunsaturated fatty acids (PUFA)
takes place at the endoplasmic membrane [58] by four distinct en-
zymes; elongation of very long chain fatty acids (ELOVL), 3-ketoacyl-
CoA reductase (HSD17B12), 3-hydroxyacyl dehydratase (HACD3) and
trans-2,3,-enoyl-CoA reductase (TECR). The initial condensation reac-
tion that is catalyzed by the enzyme ELOVL is considered to be rate lim-
iting [59].While seven different ELOVL enzymes have been identiﬁed in
mammals (designated ELOVL1-7) only a single enzyme has been iden-
tiﬁed so far for the subsequent reaction step [60]. Thus, substrate spec-
iﬁcity for the elongation reaction is conferred by ELOVL. ELOVL1,
ELOVL3, ELOVL4 and ELOVL6 are involved in the synthesis of saturated
and monounsaturated fatty acids and ELOVL2, ELOVL4, ELOVL5 and
ELOVL7 are essential for PUFAmetabolism. It was recently demonstrated
that the synthesis of C24:0 and C26:0 is carried out by the concerted ac-
tion of ELOVL6 (C18:0–C22:0) and ELOVL1 (C24:0–C26:0) [50] (Fig. 2).
Importantly, ELOVL1 knockdown reduces elongation of C22:0 to C26:0
and lowers C26:0 levels in X-ALD ﬁbroblasts [50]. Further research is
now warranted to investigate ELOVL1's therapeutic potential for X-ALD.
3. Genetic aspects of X-ALD
The ABCD1 gene (GenBank accession number: NM_000033) was
identiﬁed by the use of positional cloning strategies [43]. The gene
covers 19.9 kb, contains 10 exons and encodes a peroxisomal trans-
membrane protein of 745 amino acids with the general structure of
an ATP-binding cassette (ABC) transporter [61]. All X-ALD patients
have mutations within the ABCD1 gene, which conﬁrmed that this is
the genetic cause of X-ALD. The disorder is inherited in an X-linked
manner. Hence, if a female is a carrier for X-ALD, 50% of her daughters
will be heterozygous carriers for X-ALD and 50% of her sons will have
X-ALD. All daughters of an affected male will be carriers but none of
his sons will be affected. Wang and coworkers reported that among
489 X-ALD families tested at the Kennedy Krieger Institute, 4.1% of the
patients were affected by a de novo mutation in the index case, which
indicates that the mutation occurred in the germ line [62]. Less than
1% had evidence of gonadal or gonosomal mosaicism. The residual ma-
ternal risk for having additional ovi carrying themutant allele, however,
is at least 13%. Thus, there remains signiﬁcant reproductive risk for
transmission of the disease-causing allele to other offspring [62].
3.1. ABCD1 pseudogenes and mutation analysis
As mentioned previously, approximately 20% of obligate heterozy-
gotes have normal plasma VLCFA levels. Therefore, mutational analysis
is required for accurate identiﬁcation of women at risk to be heterozy-
gous for ABCD1 mutations and for effective mutational screening in af-
fected families. However, special care must be taken for primer
selectionwhen the ABCD1 gene is sequenced because interchromosomal
duplications of exons 7–10 to chromosomes 2q11, 10p11, 16p11 and
22q11 have occurred due to pericentromeric plasticity [63]. Comparative
sequence analysis showed that the pseudogenes share 92–96% nucleo-
tide identity with the ABCD1 gene. For conventional sequence analysis,
ABCD1 gene-speciﬁc primers have been designed [25]. It should
be stressed that the high degree of sequence identity between the
ABCD1 locus and the pseudogenes may generate problems in “next-generation-sequencing” based on complications during sequence align-
ment of short fragments derived from the different autosomal pseudo-
genes and the ABCD1 gene. Consequently, mutations in ABCD1 might
be overseen.
3.2. The nature and frequency of ABCD1 mutations
Based on mutational analysis of the ABCD1 gene in X-ALD patients,
587 different mutations have been described up to now [64] (http://
www.x-ald.nl). Of these mutations, 300 (51%) are missense mutations,
166 (28%) frame shiftmutations, 68 (12%) nonsensemutations, 35 (6%)
amino acid insertions/deletions and 18 (3%) larger deletions of one or
more exons. It is described that 77% of all non-recurrent ABCD1 muta-
tions result in the absence of ALDP (http://www.x-ald.nl). This is, on
the one hand, due to the fact that 50% of ABCD1mutations, such as non-
sense and frame shift mutations as well as larger deletions lead to a
truncated protein. On the other hand, many missense mutations result
in unstable protein; here the absence of ALDP might be a question of
sensitivity of detection. In most cases, the absence of detectable ALDP
was judged by using anti-ALDP immunoﬂuorescencemicroscopy in cul-
tured ﬁbroblasts from patients. However, ﬁbroblasts express relatively
low levels of ABCD1 and thus, in some cases a partial reduction may
lead to the complete disappearance of anti-ALDP immunoﬂuorescence,
while still being detectable by using the more sensitive western blot
method. Indeed, Zhang and coworkers developed amethod for accurate
quantiﬁcation of low amounts of ALDP and reinvestigated ALDP expres-
sion in cell lines that had been scored previously ALDP negative based
on immunoﬂuorescence [22]. This revealed that residual ALDP is detect-
able in all analyzed cell lines with a missense mutation, but the levels
were often below the level of detection by immunoﬂuorescence.
Hence, ALDP could be detectable by immunohistochemistry when cell
types with high ABCD1 expression level are used. Disease-associated
missensemutations are not equally distributed over the protein. Analy-
sis of the distribution of the 300 missense mutations reveals that there
are two regions in which themajority of missense mutations are found.
The ﬁrst region is located in the transmembrane domain region be-
tween amino acids 83 and 344 and the second is located in the ATP-
binding domain between amino acids 500 and 668. The N-terminal 73
amino acids and the C-terminal 50 amino acids are mostly spared
frommissensemutations. Thus, caution iswarrantedwhen interpreting
missense mutations in this region. The mutation p.Asn13Thr, for exam-
ple, has been shown to represent a polymorphism, as this mutation did
not affect the ability to compensate for the lack of functional ALDP after
transfection [65].
3.3. Genotype and phenotype in X-ALD
In other, non-peroxisomal ABC-transporters, like for example
ABCB1 (Pgp/MDR1) or ABCA4 (ABCR), individual mutations can
lead to residual transporter capacity and, as in the case of ABCA4,
be associated with a later onset form of Stargardt disease [66].
There is no simple and general genotype–phenotype relation in X-
ALD. Large deletions, nonsense mutations or frame shift mutations
which result in the complete absence of a functional ALDP are
found in patients covering the full spectrum of X-ALD phenotypes in-
cluding very mild forms of late onset AMN. The best example for this
is the most common ABCD1 mutation, a deletion of two base-pairs
resulting in a frame shift (p.Gln472fsX83) leading to a truncated
ALDP that lacks the ATP-binding domain and is thus nonfunctional.
This micro-deletion has been identiﬁed in 81 out of 1234 analyzed
ABCD1 genes and the affected patients presented with all different
variants of X-ALD [67]. Another striking demonstration of the lack
of a simple genotype–phenotype correlation is the presence of ﬁve
different phenotypes in six male patients of a family with a destabi-
lizing missense mutation, p.Pro484Arg [68]. These observations
clearly demonstrate that the total lack of a functional ALDP
Fig. 2. Very long-chain fatty acids (VLCFA) are synthesized through elongation of long-chain fatty acids. VLCFA synthesis involves the elongases ELOVL6 (C18:0–C22:0) and ELOVL1
(C24:0–C26:0). ALDP transports C24:0/C26:0-CoA across the peroxisomal membrane. A deﬁciency in ALDP impairs peroxisomal VLCFA beta-oxidation but also raises cytosolic
levels of C24:0/C26:0-CoA which are substrate for further elongation by ELOVL1 (adapted from [51]).
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ALD. Thus, additional factors are required to initiate the inﬂammato-
ry process. Head trauma has been described as one of several possi-
ble “environmental” risk factors able to trigger the rapidly
progressive inﬂammatory demyelination in AMN patients [69].
However, this does not exclude that some mutations with residual
transporter activity might exclusively lead to AMN, irrespective of
other factors. For example, a Dutch kindred has been described in
which all heterozygous females are asymptomatic and all X-ALD
males are either still asymptomatic at old age or show mild pheno-
types including gonadal insufﬁciency and AMN without cerebral in-
volvement [64]. The affected members of this kindred carry a
missense mutation p.Arg389His that results in stable ALDP correctly
localized to peroxisomes. This mutation may thus represent such a
rare variant of a genotype–phenotype relation.3.4. Genetic modiﬁers in X-ALD
Segregation analysis suggests that in addition to the disease caus-
ing ABCD1mutations and environmental factors, other genetic auto-
somal inherited factors are involved in the clinical manifestation of
X-ALD [70,70,71]. The demonstration that ALDP-related protein
(ALDRP, ABCD2), the closest homolog of ALDP, has an overlapping
function with ALDP [72] suggested the ABCD2 gene as a putative X-
ALD modiﬁer gene. However, sequence and segregation analyses of
the ABCD2 gene in a large X-ALD family with different phenotypes,
as well as two independent association studies of polymorphisms
and clinical phenotypes excluded ABCD2 as a major modiﬁer locus
in X-ALD [73,74]. Investigations of other candidate genes such as
the HLA haplotype have shown conﬂicting results [75,76], but these
analyses may have been performed in underpowered sample collec-
tives making a ﬁnal conclusion uncertain. However, positive associa-
tion studies with variants in genes involved in methionine
metabolism [77,78], and SOD2 [79], or altered gene expression of
Bubblegum (a member of the VLCFacyl-CoA synthetase family)
[34], and ABCD4 (PMP69/P70R, another half ABC-transporter with
high homology to ALDP) [34], might indicate their involvement in
the pathology of X-ALD. Also, detailed investigations of the CD1
gene cluster involving 23 carefully selected tag-SNPs within this
gene region in 87 childhood cerebral ALD and 52 pure-AMN patients
(deﬁned as older than 45 years and without cerebral involvement)identiﬁed one SNP, rs973742, located 4 kb downstream from the
CD1D gene. The minor allele was signiﬁcantly more frequent in
pure-AMN patients (χ2=7.6; P=0.006). However, this association
was no longer statistically signiﬁcant after Bonferroni correction
for multiple testing [80]. This is a general problem associated with
rare diseases in which the sample size is relatively small, but never-
theless it likely provides evidence for a possible involvement in the
molecular mechanism of X-ALD. ELOVL1 is another candidate modiﬁ-
er gene based on its important function in VLCFA synthesis [50]. In-
terestingly, a SNP has been identiﬁed in the promoter region of the
ELOVL1 (Kemp and Aubourg, unpublished observations). The func-
tional effect of this SNP is under investigation. In summary, it
seems unlikely that there is a single modiﬁer locus that allows the
prediction of the future phenotypic outcome for a presymptomatic
X-ALD patient. The data currently available point to the existence
of many rare genetic variant interactions that affect the clinical man-
ifestations in X-ALD patients. This is the experience that is observed
in many multifactorial diseases [81].3.5. Prenatal diagnosis
Prenatal diagnosis to detect a possible affected male fetus can be
offered to women whose heterozygous status has been clearly con-
ﬁrmed by genetic analysis of the ABCD1 gene. In some countries,
noninvasive prenatal determination of fetal sex using cell-free fetal
DNA present in maternal blood may be performed at 7 weeks of
pregnancy. It relies upon the detection of Y chromosome sequences
by PCR techniques [82]. If the fetus is a male, ABCD1mutational anal-
ysis can be performed on a fresh chorionic villus sample (CVS) at
11–13 weeks of pregnancy. Alternatively, the determination of fetal
sex can be performed by conventional cytogenetic techniques on a
CVS sample at 11–13 weeks of pregnancy and then ABCD1mutation-
al analysis performed if the fetus is a male. Mutation analysis takes a
few days. Prenatal diagnosis can also be done on amniotic cells at
15–18 weeks of gestation. This approach, however, requires at least
an additional 2–3 weeks of amniotic cell culture in order to generate
enough cell material for molecular analysis. In case the ABCD1muta-
tion has not yet been identiﬁed in the family, but the heterozygous
status of the female has been clearly established biochemically by
the demonstration of increased VLCFA levels in her plasma, prenatal
diagnosis of a male fetus has to be done by the measurement of
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genetic diagnosis can also be offered in some countries for selected
cases. Usually this is done when a heterozygous female has had at
least two prenatal diagnoses leading to pregnancy interruption
because the fetus was an X-ALD male. A signiﬁcant number of het-
erozygous women develop AMN in adulthood and prenatal diagnosis
of a female fetus to establish whether the fetus has X-ALDmay be of-
fered on an individual basis. This situation occurs more andmore fre-
quently when either the father or the pregnant mother has severe
AMN.
4. Pathophysiology of X-ALD
4.1. AMN
AMN, the most frequent phenotype of X-ALD, is nearly completely
penetrant in adult males and affects 65% of heterozygous women by
the age of 60 years (Engelen et al., manuscript in preparation). The
Abcd1 knockout mouse develops a phenotype that resembles AMN
at 18–20 months of age, but no cerebral demyelination [40]. The neu-
ropathological hallmark of AMN is an axonopathy with microgliosis
but without signiﬁcant myelin changes [83]. In the CNS, ALDP is most-
ly expressed in oligodendrocytes, microglia, astrocytes and endothe-
lial cells [84], but not in most neurons with the exception of
hypothalamus, basal nucleus of Meynert, periaqueductal gray matter
and in the locus coeruleus [85]. A direct role for oligodendrocytes to
sustain axonal function is supported by the observation that mice
lacking 2′,3′-cyclic nucleotide phosphodiesterase (CNPase) or proteo-
lipid protein (PLP) display axonal dysfunction without demyelination
in the spinal cord and brain [86,87]. It is therefore possible that the
primary consequence of the loss of ALDP function in oligodendrocytes
triggers progressive axonal damage without signiﬁcant demyelin-
ation. Conﬁrmation that this hypothesis is correct would require the
targeted inactivation of the Abcd1 gene speciﬁcally in mouse oligo-
dendrocytes and follow up to evaluate whether these mice indeed de-
velop the AMN-like phenotype. In X-ALD patients, this degenerative
process, however, is very slow and takes decades to ﬁnally result in
clinical symptoms of AMN. Interestingly, Abcd1 knockout mice dis-
play oxidative damage to proteins in the spinal cord already at the
age of 3 months [39], long before the ﬁrst neuropathological lesions
in the spinal cord at around 16 months of age and clinical signs at
20 months of age [40]. Loss of function of ALDP and possibly the accu-
mulation of VLCFA result in oxidative stress in oligodendrocytes. This
oxidative stress and/or antioxidant defense impairment in oligoden-
drocytes could be the major factor that initiates axonal damage in
X-ALD. This notion is supported by the observation that antioxidants
reduce markers for oxidative stress and axonal degeneration in the
spinal cord of Abcd1 knockout mice [88]. Yet, recent transcriptomic
analysis highlighted other pathways that are dysregulated in Abcd1
knockout mice, including oxidative phosphorylation, adipocytokine
and insulin signaling pathways, protein synthesis and turnover, NF-
kappa B mediated pro-inﬂammatory response, inﬂammatory re-
sponse related to TGF beta, and the Toll-like receptor pathway [89].
Consistent with the microgliosis observed at the neuropathological
level, these data suggest that a pro-inﬂammatory status is also pre-
sent in AMN.
4.2. Cerebral demyelination
Not all X-ALD males develop cerebral demyelination with severe
neuroinﬂammation. Because of the absence of general genotype–phe-
notype correlation in X-ALD, it is likely that a combination of genetic,
epigenetic and environmental factors play an essential role as triggers
for the development of cerebral ALD. This is supported by the devel-
opment of different clinical phenotypes in monozygotic twins
[90,91] and the observation that moderate head trauma can initiatecerebral demyelination in AMN patients [69]. Even though there is
no correlation between the levels of VLCFA in plasma or ﬁbroblasts
and the X-ALD phenotype, VLCFA are highly elevated in myelin-
speciﬁc lipid species [18,26–29]. These VLCFA-enriched complex
lipids could be a key factor that contributes to the initiation of myelin
instability and then cerebral demyelination. Indeed, VLCFA levels are
higher in the normal appearing white matter of patients with cerebral
ALD than in the normal white matter of AMN patients [34]. In line
with this, oligodendrocytes derived from induced pluripotent stem
cells from a patient with cerebral ALD accumulated more VLCFA
than those derived from an AMN patient [92]. The synthesis of
VLCFA (C26:0) is enhanced in X-ALD [56] and it requires the elon-
gases ELOVL6 and ELOVL1 [50,51]. Genetic polymorphism in these
elongases may affect the further elongation of C26:0 acyl-CoA esters
into even longer fatty acids that would result in more sustained my-
elin sheath instability. It has been hypothesized that secondary per-
oxisomal dysfunction may contribute to cerebral demyelination and
even neuroinﬂammation in X-ALD [93]. This hypothesis is based on
the observation that mice lacking functional peroxisomes in oligo-
dendrocytes initially show normal myelination, but develop axonal
swelling followed by cerebral demyelination and inﬁltration of in-
ﬂammatory T cells [94].
Plasmalogens are reduced in the brain lesions of cerebral ALD pa-
tients [95]. A decrease in plasmalogen levels could alter the transport
of cholesterol which is an essential component of the myelin sheath
[96], it could increase the oxidation of cholesterol in phospholipid bila-
yers [97]which in turnmay result in cytotoxic, oxidative and inﬂamma-
tory activities [98] and increased oxidative stress in glial cells [99].
As mentioned before, a pro-inﬂammatory status is present in Abcd1
knockout mice that do not develop cerebral demyelination. Polymor-
phisms in genes involved in the different pathways that promote
or counteract this pro-inﬂammatory stage may also play an
important role in advancing or preventing the transition from a pro-
inﬂammatory to a full-blown neuroinﬂammatory stage. The accumula-
tion of T and B lymphocytes beyond the actively demyelinating lesions
in the brain are strongly suggestive of an immune attack [100].
Candidate antigens include VLCFA-enriched complex lipids that are
recognized by the CD1 molecules that play a major role in MHC-
unrestricted lipid antigen presentation. The presence of these lipid anti-
gens, does not exclude the participation of protein antigens as the cause
of the immune attack in X-ALD.
It is also likely that microglia with normal ALDP function play a sig-
niﬁcant role in halting the initiation and progression of cerebral demy-
elination with neuroinﬂammation. This is strongly supported by the
fact that both allogeneic hematopoietic stem cell (HSC) transplantation
and autologous HSC gene therapy are very effective in arresting and
even reversing neuroinﬂammatory cerebral ALD, provided that the pro-
cedure is performed at an early stage [101,102].
For the majority of X-ALD patients, including males and females
with AMN, as well as males with too advanced cerebral demyelinating
disease for allogeneic HSC transplantation to be effective, treatment op-
tions are very limited andmostly symptomatic [103]. Research targeted
at understanding the pathophysiology observed in the X-ALD mouse
has resulted in novel therapeutic strategies that could potentially halt
or slow down the neuroinﬂammation process and/or axonal degenera-
tion [104]. More basic research is however crucial to create a clear pic-
ture of the various pathophysiological aspects of X-ALD. In this
respect, the absence of a relevant X-ALDmousemodel that develops ce-
rebral demyelination with neuroinﬂammation is a major limitation in
deciphering themechanism underlying the onset of cerebral inﬂamma-
tory demyelination in X-ALD.
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